Biological properties of drug targets. Genomic signatures of drug targets for breast cancer (BrCa), pancreatic cancer (PaCa) and ovarian cancer (OvCa) are shown. (A) Overview of the systematic pipeline to identify and validate novel anti-cancer drug targets. (B) Gene essentiality, (C) mRNA expression, (D) DNA copy number, (E) mutation occurrence, (F) mutation pattern and (G) position enrichment of known cancer drug targets (black bars) and putative non-drug targets (gray bars) are compared. Error bars indicate standard deviation of drug targets.